ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

Anders Sundin(Uppsala University), Rudolf Arnold(Philipps University of Marburg), Éric Baudin(Institut Gustave Roussy), Jarosław B. Ćwikła(University of Warmia and Mazury in Olsztyn), Barbro Eriksson(Uppsala University), Stefano Fanti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Nicola Fazio(European Institute of Oncology), Francesco Giammarile(Université Claude Bernard Lyon 1), Rodney J. Hicks(Peter MacCallum Cancer Centre), Andreas Kjær(University of Copenhagen), Eric P. Krenning(Erasmus MC), Dik J. Kwekkeboom(Erasmus MC), Catherine Lombard‐Bohas(Hospices Civils de Lyon), Juan Manuel O’Connor(Instituto Alexander Fleming), Dermot O’Toole(Trinity College Dublin), Andrea Rockall(Royal Marsden NHS Foundation Trust), Bertram Wiedenmann(Charité - Universitätsmedizin Berlin), Juan W. Valle(University of Manchester), Marie‐Pierre Vullierme(Hôpital Beaujon), all other Antibes Consensus Conference participants
Neuroendocrinology
January 1, 2017
Cited by 491Open Access
Full Text

Abstract

Contrast-enhanced computed tomography (CT) of the neck-thorax-abdomen and pelvis, including 3-phase examination of the liver, constitutes the basic imaging for primary neuroendocrine tumor (NET) diagnosis, staging, surveillance, and therapy monitoring. CT characterization of lymph nodes is difficult because of inadequate size criteria (short axis diameter), and bone metastases are often missed. Contrast-enhanced magnetic resonance imaging (MRI) including diffusion-weighted imaging is preferred for the examination of the liver, pancreas, brain and bone. MRI may miss small lung metastases. MRI is less well suited than CT for the examination of extended body areas because of the longer examination procedure. Ultrasonography (US) frequently provides the initial diagnosis of liver metastases and contrast-enhanced US is excellent to characterize liver lesions that remain equivocal on CT/MRI. US is the method of choice to guide the biopsy needle for the histopathological NET diagnosis. US cannot visualize thoracic NET lesions for which CT-guided biopsy therefore is used. Endocopic US is the most sensitive method to diagnose pancreatic NETs, and additionally allows for biopsy. Intraoperative US facilitates lesion detection in the pancreas and liver. Somatostatin receptor imaging should be a part of the tumor staging, preoperative imaging and restaging, for which <sup>68</sup>Ga-DOTA-somatostatin analog PET/CT is recommended, which is vastly superior to somatostatin receptor scintigraphy, and facilitates the diagnosis of most types of NET lesions, for example lymph node metastases, bone metastases, liver metastases, peritoneal lesions, and primary small intestinal NETs. <sup>18</sup>FDG-PET/CT is better suited for G3 and high G2 NETs, which generally have higher glucose metabolism and less somatostatin receptor expression than low-grade NETs, and additionally provides prognostic information.


Related Papers

No related papers found

Powered by citation graph analysis